Screener
Viking Therapeutics VKTX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $67,183 | $53,251 |
| Other accrued liabilities | 39,142 | 23,279 |
| Lease liability, current | — | 137 |
| Total current liabilities | 106,325 | 76,667 |
| Total liabilities | 106,325 | 76,667 |
| Commitments and contingencies (Note 7) |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's accrued expenses?
- Viking Therapeutics (VKTX) reported accrued expenses of $39.14M in Q1 2026.
- How has Viking Therapeutics's accrued expenses changed year-over-year?
- Viking Therapeutics's accrued expenses increased by 244.2% year-over-year, from $11.37M to $39.14M.
- What is the long-term trend for Viking Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Viking Therapeutics's accrued expenses has grown at a 24.4% compound annual growth rate (CAGR), from $7.81M to $23.28M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Viking Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude